Abstracts & Articles

Abstracts

  • Presented to the International Anesthesia Research Society (IARS) 2015: 
    Werneid K, Riazi S, Brandom BW: Long-term sequelae in patients who experienced a malignant hyperthermia event.
  • Presented to the American Society of Anesthesiologists (ASA) 2013: 
    Larach MG, Brandom BW, Allen GC, Gronert GA: Failure to rescue from fulminant malignant hyperthermia: deaths and their genetic variants 2007-2012.
  • Presented to the American Society of Anesthesiologists (ASA) 2011: 
    Brandom BW, Wilde J, Young MC: Chronic pain symptoms in malignant hyperthermia.
  • Presented to the European Malignant Hyperthermia Group 2010: 
    Brandom BW, Muldoon, SM, Sambuughin N: More than Anesthetic Induced Malignant Hyperthermia (MH).
  • Presented to the European Malignant Hyperthermia Group 2009: 
    Brandom BW, Muldoon SM, Wong C, Rosenberg H, Tautz T, Sambuughin N: An Update on the Ryanodine Receptor Gene Variants found in the USA.
  • Presented to the American Society of Anesthesiologists (ASA) 2008: 
    Larach MG, Allen GC, Brandom BW, Gronert GA, Lehman EB: Temperature changes are not late signs of malignant hyperthermia: A NAMH Registry of MHAUS Study
  • Presented to the American Society of Anesthesiologists (ASA) 2008: 
    Scientific Papers, in review. Larach MG, Allen GC, Brandom BW, Gronert GA, Lehman EB: Serious complications associated with malignant hyperthermia events: A NAMH Registry of MHAUS Study.
  • Presented to the American Society of Anesthesiologists (ASA) 2007: 
    Sambuughin N, Brandom B, Capacchione J, Rosenberg H, Muldoon S: Toward updating the North American Malignant Hyperthermia Mutation Panel.
  • Presented to the American Society of Anesthesiologists (ASA) 2006: 
    Larach MG, Brandom BW, Allen GC, Gronert GA, Lehman EB: Deaths associated with malignant hyperthermia (1987-2006). A North American MH Registry of MHAUS Study.
  • Presented to the American Society of Anesthesiologists (ASA) 2005: 
    Torp KD, Brandom BW, Capacchione JF, Voelkel ML, Muldoon SM: Caffeine halothane contracture test and ryanodine receptor type 1 analysis in patients who experienced MH episodes.
  • Presented to the American Society of Anesthesiologists (ASA) in 2005: 
    Burkman JM, Posner KL, Domino KB: Analysis of the clinical variables associated with recrudescence after malignant hyperthermia reactions.
  • Presented to the American Society of Anesthesiologists (ASA) in 2004:
    Sambuughin N, Holley H, Brandom B, Nelson T, Muldoon S: Comprehensive screening of the RYR1 gene for malignant hyperthermia susceptibility.
  • Presented to the European Congress of Nursing in 2004,
    previously presented to the American Association of Nurse Anesthethists 2003:

    Ciceron MC, Lauriello R, McCarthy EJ, McDonough JP: Differences in clinical manifestations in malignant hyperthermia episodes with succinylcholine or volatile anesthetics.
  • Presented to the Society for Pediatric Anesthesia 2003: 
    Brandom BW, Larach MG, Gurgis F: Comparison of pediatric and adult patients with regard to the safety and efficacy of dantrolene.
  • Presented to the American Society of Anesthesiologists 2002: 
    Kozack JK: A survey of chronic muscle pain and other symptoms in malignant hyperthermia susceptible individuals.
  • Presented to the American Society of Anesthesiologists 2002: 
    Brandom BW, Larach MG: Reassessment of the safety and efficacy of dantrolene.

Articles

The following articles include data from or otherwise depend upon the North American MH registry.

  • Larach, MG. A primer for diagnosing and managing malignant hyperthermia susceptibility.  Anesthesiology 2018; 128:8-10
  • Butala, B. & Brandom, B. Muscular body build and male sex are independently associated with malignant hyperthermia susceptibility. Can J Anesth/J Can Anesth. 2017; 64: 396
  • Joseph M, Theroux MC, Mooney J, Falitz S, Brandom B, Byler D. Intra-operative presentation of malignant hyperthermia (confirmed by RYR1 gene mutation, c.7522C>T; p.R2508C) leads to diagnosis of King-Denborough syndrome in a child with undiagnosed myopathy.  Anesthesia Analgesia. 2016.
  • Butala BN, Kang A, Guron J, Brandom BW. Long term oral dantrolene improved muscular symptoms in a malignant hyperthermia susceptible individual. Journal of Neuromuscular Diseases. 2016; 3: 115-9.
  • Werneid K, Brandom B. Survey of long-term sequelae in survivors of a malignant hyperthermia reaction. Open Journal of Anesthesiology. 2016; 6: 1-7.
  • Brandom BW, Kang A, Sivak EL, Young MC. Update on dantrolene in the treatment of anesthetic induced malignant hyperthermia. SOJ Anesthesiol and Pain Manag. 2015; 2(2):1-6.
  • Larach MG, Brandom BW, Allen GC, Gronert GA, Lehman EB. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States. Anesth Analg 2014; 119(6): 1359-1366
  • Nelson P, Litman RS. Malignant hyperthermia in children: an analysis of the North American Malignant Hyperthermia Registry. Anesth Analg 2014; 118: 369-374
  • Visoiu M, Young MC, Wieland K, Brandom BW. Anesthetic drugs and onset of malignant hyperthermia. Anesth Analg 2014; 118: 388-396
  • Brandom BW, Bina S, Wong CA, Wallace T, Visoiu M, Isackson PJ, Vladutiu GD, Sambuughin N, Muldoon SM. Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States. Anesth Analg 2013; 116:1078-86
  • Lavezzi WA, Capacchione JF, Muldoon SM, Sambuughin N, Bina S, Steele D, Brandom BW. Death in the emergency department: an unrecognized awake malignant hyperthermia-like reaction in a six-year-old. Anesth Analg 2013; 116:420-3
  • Brandom BW, Larach MG, Chen MA, Young MC. Complications associated with the administration of dantrolene 1987 to 2006: a report from the North American Malignant Hyperthermia Association of the United States. Anesth Analg 2011; 112:1115-23
  • Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg 2010; 110:498-507
  • Litman RS, Flood CD, Kaplan RF, Kim YL, Tobin JR. Postoperative malignant hyperthermia; an analysis of cases from the North American Malignant Hyperthermia Registry. Anesthesiology 2008; 109:825-9
  • Larach MG, Brandom BW, Allen GC, Gronert GA, Lehman EB. Cardiac arrests and deaths associated with malignant hyperthermia in North America from 1987 to 2006. Anesthesiology 2008; 108:603-11
  • Newmark JL, Voelkel M, Brandom BW, Wu J. Delayed onset of malignant hyperthermia without creatine kinase elevation in a geriatric, ryanodine receptor type 1 gene compound heterozygous patient. Anesthesiology 2007; 107(2):350-3
  • Burkman JM, Posner KL, Domino KB. Analysis of the clinical variables associated with recrudescence after malignant hyperthermia reactions. Anesthesiology 2007; 106:901-6
  • Fink EL, Brandom BW, Torp KD. Heat stroke in the super-sized athlete. Pediatric Emergency Care 2006; 22: 510-3
  • Sambuughin N, Holley H, Muldoon S, Brandom BW, de Bantel AM, Tobin JR, Nelson TE, Goldfarb LG. Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the North American Population. Anesthesiology 2005; 102:515-521
  • Sei Y, Sambuughin NN, Davis EJ, Sachs D, Cuenca B, Brandom BW, Tautz T, Rosenberg H, Nelson TE, Muldoon SM. Malignant hyperthermia in North America; Genetic screening of the three hot spots in the type I ryanodine receptor gene. Anesthesiology 2004; 101:824-830
  • Muldoon SM, Deuster P, Brandom BW, Bunger R: Is there a link between malignant hyperthermia and exertional heat illness. Exercise and Sport Sciences Reviews 2004; 32:174-179
  • Sei Y, Sambuughin NN, Davis EJ, Sachs D, Cuenca PB, Brandom BW, Tautz T, Rosenberg H, Nelson TE, Muldoon SM: Malignant Hyperthermia in North America: genetic screening of the three hot spots in the type I ryanodine receptor gene. Anesthesiology 2004; 101:824-830
  • Sei Y, Brandom BW, Bina S, Hosio E, Gallagher KL, Wyre HW, Pudimat PA, Holman SJ, Venzon DJ, Daly JW, Muldoon SM: Patients with malignant hyperthermia demonstrate an altered calcium control mechanism in B lymphocytes. Anesthesiology 2002; 97:1052-1058
  • Allen GC, Larach MG, Kunselman AR, The North American MH Registry: The sensitivity and specificity of the caffeine halothane contracture test. Anesthesiology 1998; 88:579-588
  • Albrecht A, Wedel DJ, Gronert GA: Masseter muscle rigidity and non-depolarizing neuromuscular blocking agents. Mayo Clin Proc 1997; 72:329-332
  • Larach MG, Rosenberg H, Gronert GA, Allen GC: Hyperkalemic cardiac arrest during anesthesia in infants and children with occult myopathies. Clin Pediatr (Phila) 1997; 36:9-16
  • Antognini JF: Creatine kinase alterations after acute malignant hyperthermia episodes and common surgical procedures. Anesth Analg 1995; 81:1039-1042
  • Larach MG, Localio AR, Allen GC, Denborough MA, Ellis FR, Gronert GA, Kaplan RF, Muldoon SM, Nelson TE, Ording H, et al: A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80:771-779
  • Larach MG, Landis JR, Bunn JS, Diaz M, The North American MH Registry: Prediction of malignant hyperthermia susceptibility in low-risk subjects. Anesthesiology 1992; 76:16-27
  • Larach MG: Standardization of the caffeine halothane muscle contracture test, North American Malignant Hyperthermia Group. Anesth Analg 1989; 69:511-515